Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

07 April 2022

Sustainable Views, Financial Times: Healthcare stewards see success on access to vaccines

The Access to Medicine Foundation's Director of Strategy, Damiano de Felice, spoke with Financial Times journalist Angus Peters for an article examining how the pandemic has brought the issue of global access into the mainstream for investors in pharmaceutical companies.

“Every day we get more requests from investors who want to know more about the topic and how to work with us," Damiano said, highlighting the impact of the Foundation's Access to Medicine Index Statement, as well as the Investor Action on Antimicrobial Resistance Initiative. 

The article is published as part of Sustainable Views at esg-specialist.com, which is the Financial Times's new prototype publication aimed at financial services professionals. This "aims to be the authoritative source of information on developments in sustainability policy and regulation, the impact of environmental, social and governance factors on capital markets, and the transition to a green and just economy."

The article outlines examples of how investors have pressed for, and achieved, progress on global access issues at some of the world's largest pharmaceutical companies. 

Damiano told the publication that investor coalitions and groups have now reached critical scale, saying: "This is why it’s great for us to have more than 100 investors, more that $20tn, because when our investors speak to companies they come with a sizeable ownership of the company."

Read the full article on the Sustainable Views website.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved